Related Experiment Video
Updated: Jul 2, 2025

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
Systematic Characterization of p53-Regulated Long Noncoding RNAs across Human Cancers Reveals Remarkable
Kausik Regunath1, Vitalay Fomin1, Zhaoqi Liu2
1Department of Biological Sciences, Columbia University, New York, New York.
Abstract:
The p53 tumor suppressor protein, a sequence-specific DNA binding transcription factor, regulates the expression of a large number of genes, in response to various forms of cellular stress. Although the protein coding target genes of p53 have been well studied, less is known about its role in regulating long noncoding genes and their functional relevance to cancer. Here we report the genome-wide identification of a large set (>1,000) of long noncoding RNAs (lncRNA), which are putative p53 targets in a colon cancer cell line and in human patient datasets from five different common types of cancer. These lncRNAs have not been annotated by other studies of normal unstressed systems. In the colon cancer cell line, a high proportion of these lncRNAs are uniquely induced by different chemotherapeutic agents that activate p53, whereas others are induced by more than one agent tested. Further, subsets of these lncRNAs independently predict overall and disease-free survival of patients across the five different common cancer types. Interestingly, both genetic alterations and patient survival associated with different lncRNAs are unique to each cancer tested, indicating extraordinary tissue-specific variability in the p53 noncoding response. The newly identified noncoding p53 target genes have allowed us to construct a classifier for tumor diagnosis and prognosis.
Implications:
Our results not only identify myriad p53-regulated long noncoding (lncRNA), they also reveal marked drug-induced, as well as tissue- and tumor-specific heterogeneity in these putative p53 targets and our findings have enabled the construction of robust classifiers for diagnosis and prognosis.
Insights
Researchers identified over 1,000 long noncoding RNAs (lncRNAs) regulated by the p53 protein in various cancers. These novel p53 targets show drug-induced and tissue-specific patterns, aiding in cancer diagnosis and prognosis.
Area of Science:
- Genomics
- Cancer Biology
- Molecular Oncology
Background:
- The p53 protein is a crucial tumor suppressor regulating gene expression under cellular stress.
- While p53's role in protein-coding genes is established, its regulation of long noncoding RNAs (lncRNAs) and their cancer relevance remain less understood.
Purpose of the Study:
- To identify novel p53-target lncRNAs genome-wide.
- To investigate the functional relevance of these lncRNAs in cancer, including their response to chemotherapy and their prognostic value.
Main Methods:
- Genome-wide identification of lncRNAs in a colon cancer cell line and human cancer patient datasets.
- Analysis of lncRNA induction by chemotherapeutic agents activating p53.
- Correlation of lncRNA expression with patient survival across five cancer types.
Main Results:
- Identified over 1,000 putative p53-target lncRNAs, many unannotated in normal tissues.
- Observed significant drug-induced and tissue-specific heterogeneity in p53-regulated lncRNAs.
- Demonstrated that specific lncRNAs predict patient survival, with unique patterns across different cancer types.
Conclusions:
- This study expands the known targets of p53 to include a vast number of lncRNAs.
- The findings highlight the significant heterogeneity and clinical relevance of p53-regulated lncRNAs in cancer.
- Newly identified lncRNAs can serve as robust classifiers for tumor diagnosis and prognosis.
Related Concept Videos
lncRNA - Long Non-coding RNAs
piRNA - Piwi-interacting RNAs
Abnormal Proliferation
MicroRNAs
The Nucleolus
Non-LTR Retrotransposons

